ABIONYX Pharma schedules Combined Annual General Meeting for June 30, 2026
ABIONYX Pharma has scheduled its Combined Annual General Meeting for June 30, 2026, at its registered office in Balma, France. Shareholders may vote in person or by mail, with procedures outlined in a prior BALO notice. A live broadcast will be available, though it will not support remote voting or questions.
*this image is generated using AI for illustrative purposes only.
ABIONYX Pharma will hold its Combined Annual General Meeting on June 30, 2026, at 4:00 p.m. at its registered office located at 33-43 Av. Georges Pompidou, 31130 Balma, France. The biopharmaceutical company, focused on developing therapies for sepsis and critical care, has made the preparatory documents available on its website under the "Investors" section.
Shareholders can cast their votes by attending the meeting in person or by mail using a mail-in ballot or by granting proxy to the Chair of the Meeting. The voting procedures are detailed in the prior notice published in the BALO on May 22, 2026.
For those unable to attend, ABIONYX Pharma will provide a live broadcast of the meeting via a specific link on its website. However, the broadcast will not allow for remote voting or questions. A replay of the meeting will be made available on the company's website following the event.
Meeting Details
| Detail | Information |
|---|---|
| Date | June 30, 2026 |
| Time | 4:00 p.m. |
| Location | 33-43 Av. Georges Pompidou, 31130 Balma, France |
| Notice Publication | May 22, 2026 (BALO) |
Voting Options
- Attend in person
- Vote by mail (mail-in ballot)
- Grant proxy to the Chair of the Meeting
ABIONYX Pharma specializes in innovative therapies based on a proprietary apoA-I technology platform, targeting immune-inflammatory dysregulation in sepsis and other severe diseases.
What key clinical milestones for ABIONYX's sepsis therapies are expected to be addressed during the meeting?
How might the shareholder voting outcomes influence the company's strategic direction or capital allocation?
Will management provide updated timelines or financial guidance regarding the progression of their proprietary apoA-I platform?
18
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
